On-Demand CME Videos
Optimizing The Patient Skin Cancer Journey With Gene Expression Profiling
About
This activity was recorded at the Fall Clinical Dermatology Conference 2023.
Optimizing The Patient Skin Cancer Journey With Gene Expression Profiling
This activity is supported by an educational grant from Castle Biosciences.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 6, 2023
January 1, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the role of gene expression profiling for the management of skin cancers
Describe how to integrate gene expression profiling for cutaneous melanoma and SCC to inform risk- and appropriate management decisions
Intended Audience
Faculty
Laura Ferris, MD, PhD
Professor and Director of Clinical Trials, Dermatology
University of Pittsburgh
Pittsburgh, PA
Darrell Rigel, MD, MS
Clinical Professor of Dermatology
New York University
Grossman School of Medicine
New York, NY
Adjunct Professor
UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic
Dallas, TX
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board: DermTech, Boerhinger-Ingelheim, AbbVie, Bristol-Myers Squibb, Arcutis, Dermavant, Cara Therapeutics, Leo Pharma, Regeneron, Amgen, Janssen, Novartis Grant/Research Support: AbbVie, Bristol-Myers Squibb, DermTech, Castle Biosciences, Arcutis, Amgen, Janssen, Eli Lilly, Novartis, UCB, Moberg, Aristea, Acelyrin, Cara Therapeutics, Leo Pharma, Regeneron, SkinAnalytics Consultant: DermTech, Boerhinger-Ingelheim, AbbVie, Bristol-Myers Squibb, Arcutis, Dermavant, Cara Therapeutics, Leo Pharma, Pfizer, Regeneron, Amgen, Janssen, Novartis, Sanofi Speakers’ Bureau or Honoraria: Boerhinger-Ingelheim, Bristol-Myers Squibb, Arcutis, Regeneron, Abbvie
Grant/Research Support: Castle Biosciences, SciBASE
Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics
Speakers’ Bureau or Honoraria: Castle Biosciences
Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.